Azithromycin in durasite® for the treatment of blepharitis

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 681-688

  Luchs, Jodi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Lid margin disease; Meibomian gland disease

Indexed keywords

EID: 77956131265     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s6370     Document Type: Review

References (40)

1. DateAmerican Optometric Association/date. Optometric clinical practice guideline: care of the patient with ocular surface disorders. 2002. Available from: http://www.aoa.org/documents/CPG-10.pdf Accessed Jan 14, 2010.
2. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43(2):170-179.
3. Smith RE, Flowers CW. Chronic blepharitis: a review. CLAO J. 1995; 21(3):200-207.
4. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003; 1:107-126.
5. DateAmerican Academy of Ophthalmology/date. Preferred practice patterns: blepharitis. 2008. Available from: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx Accessed Jan 20, 2010.
6. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a surveybased perspective on prevalence and treatment. Ocul Surf. 2009;7 Suppl 2:S1-S14.
7. dateCampbell Alliance Group/date. Patterns of practice and prevalence rates for lid margin disease. 2008 July-Aug.
8. Venturino G, Bricola G, Bagnis A, Traverso CE. Chronic blepharitis: treatment patterns and prevalence. Invest Ophthalmol Vis Sci. 2003;44 [E-Abstract 774].
9. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. Optom Vis Sci. 1990;67:710-712.
10. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-356.
11. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother. 1998;41 Suppl B:47-50.
12. Jacot JL, Jacot TA, Sheppard JD, et al. Evaluation of MMP 2/9 modulation by AzaSite and DuraSite in human corneal epithelial cells and bovine corneal endothelial cells in vitro. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008 Apr 28.
13. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007;26(1):42-46.
14. Pecosky DA, Robinson JR. Bioadhesive polymers and drug delivery. In: Tarcha PJ, editor. Polymers for Controlled Drug Delivery. Boca Raton, FL: CRC Publications; 1991:100-122.
15. Lux A, Maier S, Dinslage S, et al. A comparative bioavailability study of three conventional eye drops versus a single lyophilisate. Br J Ophthamol. 2003;87(4):436-440.
16. Protzko E, Bowman L, Abelson M, Shapiro A; for AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007; 48(8):3425-3429.
17. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433-439.
18. Friedlander MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1(1):3-10.
19. Kowalski RP, Yatea KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987-1991.
20. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patters of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea. 2009;28:68-72.
21. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987;31(12)1939-1947.
22. Pechere JC. Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity. Pathol Biol (Paris). 1995;43(6):483-487.
23. Brown BA, Wallace RJ Jr, Onyi GO, de Rosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonaelike organisms. Antimicrob Agents Chemother. 1992;36(1):180-184.
24. Torkildsen G, O'Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther. 2008;30(11):2005-2014.
25. AzaSite [package insert]. Durham, NC: Inspire Pharmaceuticals; 2008.
26. Abelson M, Protzko E, Shapiro A, Graces-Soldana A, Bowman L; for the 1% azithromycin in DuraSite Clinical Study Group. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007;1(2): 177-182.
27. Vigamox [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2008.
28. Zymar [package insert]. Irvine, CA: Allergan, Inc; 2004.
29. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
30. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exper Ther. 2000;292(1):156-163.
31. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Review. J Antimicrob Chemother. 2005;55:10-21. Epub 2004 Dec 8.
32. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Review. Paediatr Respir Rev. 2005;6:227-235.
33. Zhou N, Ma P, Li D-Q, Pflugfelder SC. Azithromycin suppresses proinflammatory mediators stimulated by a TLR2 ligand zymosan in human corneal epithelial cells. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009 May 3-7.
34. Sadrai Z, Hajrasouliha AR, Chauhan SK, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on innate immune responses in experimental keratitis. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009 May 3-7.
35. Stewart WC, Crean CS, Zink RC, Haque R, Hwang DG. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009 May 3-7.
36. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25(9):858-870.
37. Trattler WB, Kuhn KL, Haque R, Zink RC, Sall KN, Luchs J. Topical azithromycin improves blepharitis signs and symptoms. San Francisco, CA: American Society of Cataract and Refractive Surgery; 2009 Apr 3-8.
38. Touhey D, Shapiro A, Torkildsen G, et al. Eff icacy of topical azithromycin ophthalmic solution 1% in the treatment of chronic blepharitis patients. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009 May 3-7.
39. Haque RM, Torkildsen GL, Brubaker K, et al. Multi-center, open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. In press.
40. Foulks GN, Borchman D, Yappert M. Modification of meibomian gland lipids by topical azithromycin. Ft. Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2009 May 3-7.